Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

Por Achhra, Amit C, Boyd, Mark A
Publicado em 2013

Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV

Por Jansson, James, Wilson, David P., Carr, Andrew, Petoumenos, Kathy, Boyd, Mark A.
Publicado em 2013

Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial

Por Achhra, Amit C., Boyd, Mark A., Law, Matthew G., Matthews, Gail V., Kelleher, Anthony D., Cooper, David A.
Publicado em 2014

The Potential Cost and Benefits of Raltegravir in Simplified Second-Line Therapy among HIV Infected Patients in Nigeria and South Africa

Por Schneider, Karen, Nwizu, Chidi, Kaplan, Richard, Anderson, Jonathan, Wilson, David P., Emery, Sean, Cooper, David A., Boyd, Mark A.
Publicado em 2013

Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region

Por Wright, Stephen, Boyd, Mark A., Yunihastuti, Evy, Law, Matthew, Sirisanthana, Thira, Hoy, Jennifer, Pujari, Sanjay, Lee, Man Po, Petoumenos, Kathy
Publicado em 2013

Determinants of Viraemia Copy-Years in People with HIV/AIDS Following Initiation of Antiretroviral Therapy

Por Wright, Stephen T, Hoy, Jennifer, Mulhall, Brian, O’Connor, Catherine C, Petoumenos, Kathy, Read, Timothy, Smith, Don, Woolley, Ian, Boyd, Mark A
Publicado em 2014

HIV care in Yangon, Myanmar; successes, challenges and implications for policy

Por Aung, Ne Myo, Hanson, Josh, Kyi, Tint Tint, Htet, Zaw Win, Cooper, David A., Boyd, Mark A., Kyi, Mar Mar, Saw, Htin Aung
Publicado no AIDS Res Ther (2017)

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

Por Martin, Allison, Moore, Cecilia, Mallon, Patrick W.G., Hoy, Jennifer, Emery, Sean, Belloso, Waldo, Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Publicado em 2013

Recent trends in early stage response to combination antiretroviral therapy in Australia

Por McManus, Hamish, Hoy, Jennifer F, Woolley, Ian, Boyd, Mark A, Kelly, Mark D, Mulhall, Brian, Roth, Norman J, Petoumenos, Kathy, Law, Matthew G
Publicado em 2014

A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection

Por Holt, Stephen G, Gracey, David M, Levy, Miriam T, Mudge, David W, Irish, Ashley B, Walker, Rowan G, Baer, Richard, Sevastos, Jacob, Abbas, Riaz, Boyd, Mark A
Publicado no AIDS Res Ther (2014)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-L...

Por Martin, Allison, Moore, Cecilia L., Mallon, Patrick W. G., Hoy, Jennifer F., Emery, Sean, Belloso, Waldo H., Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Publicado em 2013

CD4(+) T Follicular Helper and IgA(+) B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals

Por Zaunders, John, Danta, Mark, Bailey, Michelle, Mak, Gerald, Marks, Katherine, Seddiki, Nabila, Xu, Yin, Templeton, David J., Cooper, David A., Boyd, Mark A., Kelleher, Anthony D., Koelsch, Kersten K.
Publicado no Front Immunol (2016)

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis

Por Cummins, Nathan W., Neuhaus, Jacqueline, Chu, Haitao, Neaton, James, Wyen, Christoph, Rockstroh, Jürgen K., Skiest, Daniel J., Boyd, Mark A., Khoo, Saye, Rotger, Margalida, Telenti, Amalio, Weinshilboum, Richard, Badley, Andrew D.
Publicado no EBioMedicine (2015)

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infect...

Por Amin, Janaki, Boyd, Mark A., Kumarasamy, Nagalingeswaran, Moore, Cecilia L., Losso, Marcello H., Nwizu, Chidi A., Mohapi, Lerato, Kerr, Stephen J., Sohn, Annette H., Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A.
Publicado no PLoS One (2015)

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of...

Por Amin, Janaki, Boyd, Mark A., Kumarasamy, Nagalingeswaran, Moore, Cecilia L., Losso, Marcello H., Nwizu, Chidi A., Mohapi, Lerato, Kerr, Stephen J., Sohn, Annette H., Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A.
Publicado no PLoS One (2015)